# Evonik Financials & ESG KPIs


| | |
|---|---|
| Financial KPIs Group | P. 2 |
| ESG KPIs | P. 3 |
| Segment KPIs | P. 4-6 |
| Group Income Statement | P. 7-8 |
| Group Balance Sheet | P. 9 |
| Group Cash Flow Statement | P. 10 |
| Group Net Financial Position | P. 11 |
| Definitions | P. 12 |


As of Q3 2026 (published November 03, 2026)

## Evonik Group Financials

| in € million | 2021 FY | 2022 FY | 2023 FY | 2024 FY | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 | 2025 FY | 2026 Q1 | 2026 Q2 | **2026 Q3** |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **External Sales** | **14,955** | **18,488** | **15,267** | **15,157** | **3,777** | **3,499** | **3,391** | **3,402** | **14,069** | **3,427** | **3,893** | **3,825** |
| Growth (%) | 23 | 24 | -17 | -1 | -1 | -11 | -12 | -5 | -7 | -9 | 11 | 13 |
| Volumes (%) | 11 | -4 | -8 | 4 | 2 | -4 | -6 | 2 | -2 | -2 | 7 | 2 |
| Prices (%) | 12 | 18 | -3 | -2 | -2 | -1 | -1 | -2 | -1 | -1 | 7 | 10 |
| Exchange Rates (%) | -2 | 5 | -2 | -1 | 1 | -3 | -3 | -5 | -2 | -5 | -2 | 0 |
| Other (incl. M&A) (%) | 2 | 5 | -4 | -2 | -2 | -3 | -2 | 0 | -2 | -1 | -1 | 1 |
| **Adjusted EBITDA** | **2,383** | **2,490** | **1,656** | **2,065** | **560** | **509** | **448** | **357** | **1,874** | **475** | **630** | **629** |
| Margin (%) | 15.9 | 13.5 | 10.8 | 13.6 | 14.8 | 14.5 | 13.2 | 10.5 | 13.3 | 13.9 | 16.2 | 16.4 |
| Adjusted EBIT | 1,338 | 1,350 | 521 | 1,027 | 309 | 250 | 197 | 105 | 861 | 235 | 370 | 389 |
| Margin (%) | 8.9 | 7.3 | 3.4 | 6.8 | 8.2 | 7.1 | 5.8 | 3.1 | 6.1 | 6.9 | 9.5 | 10.2 |
| Adjustments | -165 | -408 | -764 | -450 | -10 | -14 | -222 | -37 | -283 | -6 | -207 | -395 |
| EBIT | 1,173 | 942 | -243 | 577 | 299 | 236 | -25 | 68 | 578 | 229 | 163 | -6 |
| Capital employed (annual average) | 14,799 | 16,192 | 15,406 | 14,493 | | | | | 14,038 | | | |
| **ROCE (%)** | **9.0** | **8.3** | **3.4** | **7.1** | | | | | **6.1** | | | |
| **Free Cash Flow** | **950** | **785** | **801** | **873** | **195** | **-211** | **300** | **411** | **695** | **183** | **49** | **369** |
| Cash Conversion Rate[1] | 40 | 32 | 48 | 42 | | | | | 37 | | | |
| Capex (Cash outflow for investment in intangible assets, pp&e) | 865 | 865 | 793 | 840 | 190 | 176 | 181 | 201 | 748 | 224 | 180 | 193 |
| Adj. Net income | 986 | 1,054 | 370 | 777 | 275 | 160 | 128 | 71 | 634 | 158 | 296 | 330 |
| **Adjusted EPS (€)** | **2.12** | **2.26** | **0.79** | **1.67** | **0.59** | **0.34** | **0.27** | **0.16** | **1.36** | **0.34** | **0.65** | **0.71** |
| Dividend per share (€) | 1.17 | 1.17 | 1.17 | 1.17 | | | | | 1.00 | | | |
| Payout ratio (%) | 55% | 52% | 148% | 70% | | | | | 74% | | | |
| Dividend total payout | 545 | 545 | 545 | 545 | | | | | 466 | | | |
| Employees (continuing operations) | 33,004 | 34,029 | 33,409 | 31,930 | 31,585 | 31,273 | 31,297 | 31,053 | 31,053 | 30,643 | 30,356 | 30,319 |

[1] Free cash flow conversion = FCF / adj. EBITDA

EVONIK
Leading Beyond Chemistry

# Evonik Group Environment, Social & Governance KPIs

Full set of ESG KPIs published seperately on our IR website: evonik.finance/investor-relations

| | 2021 FY | 2022 FY | 2023 FY | 2024 FY | 2025 FY |
|---|---|---|---|---|---|
| **Strategy & Growth** | | | | | |
| Sales share with "Next Generation Solutions" | 41% | 43% | 43% | 45% | 48% |
| **Governance & Compliance** | | | | | |
| Training rate fighting money laundering | 96% | 97% | 98% | 99% | 100% |
| Training rate antitrust law | 83% | 85% | 89% | 90% | 91% |
| Training rate fighting corruption | 92% | 91% | 86% | 95% | 96% |
| Training rate code of conduct | 89% | 89% | 92% | 96% | 97% |
| Training rate Human Rights (new in 2024) | | | 90% | 84% | 94% |
| Training rate Data security (new in 2025) | | | | | 98% |
| **Value Chain & Products** | | | | | |
| Procurement volume (in € billion) | 10.4 | 13.6 | 11.3 | 10.5 | 9.8 |
| Production output (million metric tons) | 9.5 | 8.4 | 7.5 | 7.3 | 6.0 |
| Use of renewable raw materials in production | 9.7% | 11.1% | 12.0% | 9.0% | 10.0% |
| Raw material suppliers covered by TfS assessments | 69% | 66% | 67% | 71% | 86% |
| No. of sustainability audits (Evonik/TfS) | 284 | 378 | 492 | 596 | 605 |
| No. of sustainability assessments (Evonik/TfS) | 1,345 | 1,545 | 1,296 | 1,309 | 926 |
| R&D expenses (€ million) | 464 | 461 | 443 | 459 | 418 |
| **The environment** | | | | | |
| Scope 1 greenhouse gas emissions (thousands metric tons $CO_2$) | 4,381[a] | 4,221[a] | 3890[b] | 3,390 | 2.99 |
| Scope 2 greenhouse gas emissions (thousands metric tons $CO_2$) | 1,916[a] | 1,757[a] | 1400[b] | 1,670 | 1.36 |
| Scope 3 greenhouse gas emissions (million metric tons $CO_2$) | 23.4 | 20.5[a] | 18.9[b] | 21.6 | 19.5 |
| % Reduction in greenhouse gas emissions Scope 1 & 2 (million metric tons ( | -43 | -5[c] | -15[c] | -20 | -31 |
| Total water intake (in million m³) | 462[d] | 444[d] | 403 | 431 | 427 |
| Specific water intake (in m³ freshwater / metric ton production) | 26.8[d] | 29.5[d] | 29.9 | 32.2 | 36.7 |
| Production waste (thousand metric tons) | 342[d] | 335[d] | 287 | 306 | 272 |
| Specific production waste (in ton of waster per metric ton production) | 0.036 | 0.04 | 0.038 | 0.042 | 0.045 |
| **Employees** | | | | | |
| Early employee turnover | 2.2% | 1.9% | 2.2% | 1.7% | 5.3% |
| Continuing professional development per employee (hours) | 5 | 4 | 4 | 2 | 2.1 |
| Women at level "Executives" (circle 1) | 17.7% | 20.3% | 22.2% | 21.8% | 21% |
| Women at level "Senior management" (circle 2) | 17.6% | 17.1% | 18.5% | 19.1% | 22% |
| Women in management (circle 3) | 28.7% | 29.9% | 30.3% | 31.4% | 32% |
| Women in management (circles 1-3) | 27.9% | 29.1% | 29.6% | 30.7% | 32% |
| **Safety** | | | | | |
| Occupational health performance index | 5.6 | 5.5 | 5.5 | 5.5 | 5.6 |
| Accident frequency rate (no. of accidents / working hours)[b] | 0.19 | 0.25 | 0.21 | 0.14 | 0.18 |
| Incident frequency rate (no. of accidents / working hours)[b] | 0.48 | 0.49 | 0.43 | 0.44 | 0.44 |

a: adjusted figures corresponding to GHG Protocal Standards | b: Correction of data based on methodological improvements | c: for new target period 2021-2030 | d: data corrected for fast-close process

(for ESG KPI definitions please see separate "Definitions" page at the end of the file)

## Custom Solutions

| in € million | 2021 FY | 2022 FY | 2023 FY | 2024 FY | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 | 2025 FY | 2026 Q1 | 2026 Q2 | **2026 Q3** |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **External Sales** | **5,357** | **6,568** | **5,608** | **5,737** | **1,427** | **1,367** | **1,340** | **1,358** | **5,492** | **1,334** | **1,422** | **1,394** |
| Growth (yoy) (%) | 19 | 23 | -15 | 2 | 3 | -7 | -9 | -3 | -4 | -7 | 4 | 4 |
| Volumes (%) | 14 | -3 | -11 | 5 | 2 | -5 | -8 | 0 | -3 | -3 | 4 | 0 |
| Prices (%) | 5 | 13 | 1 | -2 | 0 | 1 | 1 | 1 | 1 | 0 | 3 | 5 |
| Exchange Rates (%) | -1 | 5 | -3 | -1 | 1 | -3 | -3 | -5 | -3 | -6 | -1 | 0 |
| Other (incl. M&A) (%) | 1 | 8 | -2 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | -2 | -1 |
| **External Sales Additives** | **3,588** | **4,523** | **3,747** | **3,908** | **974** | **942** | **899** | **868** | **3,683** | **920** | **999** | **953** |
| Volumes (%) | + | - | - | + | = | - | - | - | - | - | + | + |
| Prices (%) | + | + | = | - | = | = | = | = | = | = | + | + |
| **External Sales Care** | **1,768** | **2,045** | **1,861** | **1,829** | **453** | **425** | **441** | **491** | **1,809** | **414** | **423** | **441** |
| Volumes (%) | + | = | - | = | + | - | - | + | = | - | - | - |
| Prices (%) | + | + | + | = | - | = | + | + | = | = | + | + |
| **Adjusted EBITDA** | **1,086** | **1,162** | **852** | **978** | **256** | **254** | **215** | **184** | **909** | **227** | **271** | **231** |
| Margin (%) | 20.3 | 17.7 | 15.2 | 17.0 | 17.9 | 18.6 | 16.0 | 13.5 | 16.6 | 17.0 | 19.1 | 16.6 |
| EBITDA yoy Additives | + | + | - | + | + | - | - | = | - | - | + | + |
| EBITDA yoy Care | + | + | - | - | + | - | - | + | + | - | + | = |
| Adjusted EBIT | | | | 663 | 181 | 180 | 140 | 101 | 602 | 152 | 191 | 155 |
| EBIT | | | | 558 | 170 | 189 | 120 | 74 | 553 | 152 | 142 | -39 |
| Capital employed (annual average) | | | | 6,192 | | | | | 6,054 | | | |
| **ROCE (%)** | | | | **10.7** | | | | | **9.9** | | | |
| **Approx. Operating FCF** | | | | **600** | **44** | **112** | **172** | **314** | **642** | **40** | **138** | **65** |
| Capital expenditures | | | | 311 | 50 | 78 | 72 | 100 | 300 | 64 | 73 | 84 |
| **Employees** | | | | **9,736** | **9,746** | **9,649** | **9,644** | **9,529** | **9,529** | **9,805** | **9,774** | **9,833** |

2019-2023 figures pro-forma (unaudited)

Approx. Operating FCF provided as simplified indication only (unaudited). Calculated as adj. EBITDA, plus/minus NWC change, minus capex. Not including taxes, provisions and other items, thus not adding up to Group FCF.

For sales (volume and price) and EBITDA trends yoy ("+" or "-" in case of >2% deviation; otherwise "=")

## Advanced Technologies

| in € million | 2021 FY | 2022 FY | 2023 FY | 2024 FY | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 | 2025 FY | 2026 Q1 | 2026 Q2 | **2026 Q3** |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **External Sales** | **5,827** | **7,092** | **5,983** | **6,089** | **1,601** | **1,511** | **1,445** | **1,416** | **5,973** | **1,450** | **1,647** | **1,713** |
| Growth (yoy) (%) | 17 | 22 | -16 | 2 | 6 | -1 | -6 | -6 | -2 | -9 | 9 | 19 |
| Volumes (%) | 11 | -3 | -8 | 2 | 6 | 1 | -2 | 2 | 2 | -1 | 7 | 4 |
| Prices (%) | 8 | 20 | -4 | 0 | -3 | -1 | -1 | -3 | -2 | -1 | 5 | 14 |
| Exchange Rates (%) | -2 | 5 | -4 | -1 | 1 | -4 | -3 | -5 | -3 | -6 | -1 | 0 |
| Other (incl. M&A) (%) | 0 | 0 | 0 | 1 | 2 | 3 | 0 | 0 | 1 | -1 | -2 | 1 |
| **External Sales Organics** | **1,681** | **1,868** | **1,742** | **1,664** | **426** | **401** | **411** | **395** | **1,634** | **390** | **453** | **457** |
| Volumes (%) | + | - | - | + | + | - | + | + | + | = | + | + |
| Prices (%) | + | + | = | - | - | = | - | - | - | - | = | + |
| **External Sales Inorganics** | **2,357** | **3,031** | **2,491** | **2,490** | **621** | **614** | **595** | **566** | **2,395** | **577** | **631** | **618** |
| Volumes (%) | + | = | - | + | = | - | - | = | = | - | + | + |
| Prices (%) | + | + | = | - | = | = | = | - | = | = | = | = |
| **External Sales Animal Nutrition** | **1,789** | **2,193** | **1,750** | **1,935** | **554** | **496** | **439** | **454** | **1,944** | **484** | **563** | **638** |
| Volumes (%) | + | - | = | = | + | + | - | = | + | + | = | + |
| Prices (%) | + | + | - | + | - | - | - | - | - | - | + | + |
| **Adjusted EBITDA** | **1,233** | **1,207** | **752** | **1,023** | **291** | **266** | **202** | **185** | **944** | **241** | **333** | **377** |
| Margin (%) | 21.2 | 17.0 | 12.6 | 16.8 | 18.2 | 17.6 | 14.0 | 13.1 | 15.8 | 16.6 | 20.2 | 22.0 |
| EBITDA yoy Organics | + | = | - | - | + | - | - | - | - | + | + | + |
| EBITDA yoy Inorganics | + | + | - | + | - | = | - | + | - | + | - | + |
| EBITDA yoy Animal Nutrition | + | - | - | + | + | + | - | - | - | - | + | + |
| Adjusted EBIT | | | | 565 | 181 | 150 | 89 | 72 | 492 | 129 | 217 | 254 |
| EBIT | | | | 517 | 183 | 137 | 65 | 60 | 445 | 125 | 214 | 390 |
| Capital employed (annual average) | | | | 7,018 | | | | | 6,907 | | | |
| **ROCE (%)** | | | | **8.1** | | | | | **7.1** | | | |
| **Approx. Operating FCF** | | | | **513** | **156** | **85** | **182** | **250** | **673** | **135** | **135** | **167** |
| Capital expenditures | | | | 367 | 56 | 82 | 72 | 132 | 342 | 60 | 88 | 66 |
| **Employees** | | | | **9,568** | **9,405** | **9,312** | **9,189** | **9,177** | **9,177** | **9,458** | **9,380** | **9,364** |

2019-2023 figures pro-forma (unaudited)

Approx. Operating FCF provided as simplified indication only (unaudited). Calculated as adj. EBITDA, plus/minus NWC change, minus capex. Not including taxes, provisions and other items, thus not adding up to Group FCF.

For sales (volume and price) and EBITDA trends yoy ("+" or "-" in case of >2% deviation; otherwise "=")

## Infrastructure (SYNEQT + Oxeno businesses[1]) / Other

| in € million | 2021 FY | 2022 FY | 2023 FY | 2024 FY | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 | 2025 FY | 2026 Q1 | 2026 Q2 | **2026 Q3** |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **External Sales Infrastructure & Other** | **3,771** | **4,827** | **3,675** | **3,331** | **749** | **621** | **606** | **628** | **2,604** | **643** | **824** | **718** |
| Sales Infrastructure | | | | 3,146 | 708 | 584 | 574 | 583 | 2,449 | 577 | 749 | 648 |
| Sales Other | | | | 185 | 41 | 37 | 32 | 45 | 155 | 66 | 75 | 70 |
| **Adjusted EBITDA Infrastructure & Other** | **96** | **124** | **54** | **64** | **13** | **-11** | **31** | **-12** | **21** | **7** | **26** | **21** |
| Adj. EBITDA Infrastructure | | | | 275 | 61 | 38 | 54 | 60 | 213 | 47 | 100 | 80 |
| Adj. EBITDA Other | | | | -211 | -48 | -49 | -23 | -72 | -192 | -40 | -74 | -59 |
| Adjusted EBIT | -228 | -224 | -296 | -201 | -53 | -80 | -32 | -68 | -233 | -46 | -38 | -20 |
| EBIT | -316 | -641 | -611 | -498 | -54 | -90 | -210 | -66 | -420 | -48 | -193 | -357 |
| **Capital expenditures** | **292** | **241** | **189** | **138** | **27** | **25** | **29** | **49** | **130** | **21** | **28** | **32** |
| **Employees** | **16,116** | **16,504** | **16,184** | **12,626** | **12,434** | **12,312** | **12,464** | **12,347** | **12,347** | **11,380** | **11,202** | **11,122** |

[1] Infrastructure is comprised of two distinct businesses 1) SYNEQT = infrastructure assets in Marl and Wesseling and 2) Oxeno = C4 value chain in Marl and Antwerp

## Group Income Statement

| in € million | 2021 FY | 2022 FY | 2023 FY | 2024 FY | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 | 2025 FY | 2026 Q1 | 2026 Q2 | **2026 Q3** |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **External Sales** | **14,955** | **18,488** | **15,267** | **15,157** | **3,777** | **3,499** | **3,391** | **3,402** | **14,069** | **3,427** | **3,893** | **3,825** |
| Cost of sales | -10,925 | -14,257 | -12,567 | -11,419 | -2,769 | -2,568 | -2,775 | -2,713 | -10,825 | -2,563 | -2,931 | -2,965 |
| Gross profit on sales | 4,030 | 4,231 | 2,700 | 3,738 | 1,008 | 931 | 616 | 689 | 3,244 | 864 | 962 | 860 |
| Selling expenses | -1,717 | -2,035 | -1,836 | -1,894 | -454 | -434 | -420 | -428 | -1,736 | -419 | -460 | -497 |
| Research and development expenses | -464 | -460 | -443 | -459 | -106 | -105 | -104 | -103 | -418 | -94 | -96 | -119 |
| General administrative expenses | -546 | -554 | -488 | -740 | -126 | -125 | -111 | -112 | -474 | -114 | -130 | -253 |
| Other operating income & expenses | -138 | -252 | -186 | -89 | -25 | -33 | -7 | 13 | -52 | -9 | -115 | 1 |
| Result from investments recognized at equity | 8 | 12 | 10 | 21 | 2 | 2 | 1 | 9 | 14 | 1 | 2 | 2 |
| **Income before financial result and income taxes, cont. ops. = EBIT** | **1,173** | **942** | **-243** | **577** | **299** | **236** | **-25** | **68** | **578** | **229** | **163** | **-6** |
| Financial Result | -88 | -19 | -108 | -143 | -29 | -44 | -52 | -31 | -156 | -46 | -41 | -61 |
| Income before income taxes, continuing operations | 1,085 | 923 | -351 | 434 | 270 | 192 | -77 | 37 | 422 | 183 | 122 | -67 |
| Income taxes | -316 | -369 | -101 | -194 | -34 | -68 | -25 | -18 | -145 | -54 | -37 | 17 |
| **Income after taxes, continuing operations** | **769** | **554** | **-452** | **240** | **236** | **124** | **-102** | **19** | **277** | **129** | **85** | **-50** |
| Income after taxes, discontinued operations | -2 | 1 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income after taxes | 767 | 555 | -452 | 240 | 236 | 124 | -102 | 19 | 277 | 129 | 85 | -50 |
| thereof attributable to non-controlling interests | 21 | 15 | 13 | 18 | 3 | 4 | 4 | 1 | 12 | 4 | 1 | 3 |
| **Net income (attributable to shareholder of Evonik Industries AG)** | **746** | **540** | **-465** | **222** | **233** | **120** | **-106** | **18** | **265** | **125** | **84** | **-53** |
| EPS (€) | 1.60 | 1.16 | -1.00 | 0.48 | 0.50 | 0.26 | -0.23 | 0.04 | 0.57 | 0.27 | 0.18 | -0.11 |

## Group Adjusted Income Statement

| in € million | 2021 FY | 2022 FY | 2023 FY | 2024 FY | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 | 2025 FY | 2026 Q1 | 2026 Q2 | **2026 Q3** |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **External Sales** | **14,955** | **18,488** | **15,267** | **15,157** | **3,777** | **3,499** | **3,391** | **3,402** | **14,069** | **3,427** | **3,893** | **3,825** |
| **Adjusted EBITDA** | **2,383** | **2,490** | **1,656** | **2,065** | **560** | **509** | **448** | **357** | **1,874** | **475** | **630** | **629** |
| Adjusted depreciation and amortization | -1,045 | -1,140 | -1,135 | -1,038 | -251 | -259 | -251 | -252 | -1,013 | -240 | -260 | -240 |
| Adjusted EBIT | 1,338 | 1,350 | 521 | 1,027 | 309 | 250 | 197 | 105 | 861 | 235 | 370 | 389 |
| Adjusted net financial result | -97 | -19 | -103 | -143 | -29 | -44 | -52 | -37 | -162 | -46 | -41 | -61 |
| Adjusted D&A on intangible assets | 162 | 169 | 153 | 144 | 34 | 32 | 33 | 32 | 131 | 32 | 31 | 31 |
| **Adjusted income before income taxes** | **1,403** | **1,500** | **571** | **1,028** | **314** | **238** | **178** | **100** | **830** | **221** | **360** | **359** |
| Adjusted income taxes, continuing operations | -396 | -431 | -188 | -233 | -36 | -74 | -46 | -28 | -184 | -59 | -63 | -26 |
| **Adjusted income after taxes** | **1,007** | **1,069** | **383** | **795** | **278** | **164** | **132** | **72** | **646** | **162** | **297** | **333** |
| Adjusted non-controlling interest | -21 | -15 | -13 | -18 | -3 | -4 | 4 | -9 | -12 | -4 | -1 | 3 |
| **Adjusted net income** | **986** | **1,054** | **370** | **777** | **275** | **160** | **128** | **71** | **634** | **158** | **296** | **330** |
| **Adjusted EPS (€)** | **2.12** | **2.26** | **0.79** | **1.67** | **0.59** | **0.34** | **0.27** | **0.16** | **1.36** | **0.34** | **0.65** | **0.71** |

## Adjustments

| in € million | 2021 FY | 2022 FY | 2023 FY | 2024 FY | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 | 2025 FY | 2026 Q1 | 2026 Q2 | **2026 Q3** |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Restructuring measures | -32 | -121 | -64 | -405 | -12 | 7 | -31 | -6 | -42 | -4 | -48 | -313 |
| Acquisitions and divestments | -29 | 40 | -237 | -34 | -11 | 4 | 0 | -7 | -14 | 0 | 0 | -2 |
| Other special items | -104 | -327 | -463 | -11 | 13 | -25 | -191 | -24 | -227 | -2 | -159 | -80 |
| **= Adjustments** | **-165** | **-408** | **-764** | **-450** | **-10** | **-14** | **-222** | **-37** | **-283** | **-6** | **-207** | **-395** |

Adjustment categories changed as of December 31, 2023 to avoid overlaps between categories; prior year figures restated

EVONIK
Leading Beyond Chemistry

## Group Balance Sheet

**Assets**

| in € million | 2021 FY | 2022 FY | 2023 FY | 2024 FY | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 FY | 2026 Q1 | 2026 Q2 | **2026 Q3** |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Intangible assets | 6,045 | 5,710 | 5,525 | 5,571 | 5,426 | 5,176 | 5,131 | 5,097 | 5,122 | 5,115 | 5,090 |
| Property, plant and equipment | 6,963 | 6,962 | 6,294 | 6,450 | 6,305 | 6,127 | 5,933 | 6,006 | 6,051 | 6,035 | 5,993 |
| Right of use assets (capitalized leasing) | 608 | 972 | 965 | 947 | 905 | 867 | 893 | 892 | 867 | 782 | 775 |
| Investments recognized at equity | 81 | 88 | 52 | 49 | 51 | 45 | 45 | 45 | 46 | 42 | 44 |
| Trade accounts receivable | | | | | | 67 | 54 | 1 | 1 | 1 | 1 |
| Financial assets | 581 | 441 | 460 | 467 | 424 | 455 | 418 | 419 | 397 | 382 | 384 |
| Deferred tax assets | 1,755 | 890 | 642 | 664 | 629 | 624 | 659 | 436 | 430 | 466 | 502 |
| Other income tax assets | 16 | 19 | 20 | 25 | 24 | 22 | 22 | 22 | 22 | 63 | 64 |
| Other non-financial assets | 125 | 64 | 78 | 69 | 110 | 71 | 87 | 96 | 90 | 71 | 69 |
| **Non-current assets** | **16,174** | **15,146** | **14,036** | **14,242** | **13,874** | **13,454** | **13,242** | **13,014** | **13,026** | **12,957** | **12,922** |
| Inventories | 2,548 | 2,820 | 2,349 | 2,662 | 2,751 | 2,649 | 2,555 | 2,300 | 2,429 | 2,682 | 2,792 |
| Other income tax assets | 199 | 98 | 209 | 166 | 138 | 103 | 86 | 94 | 95 | 78 | 66 |
| Trade accounts receivable | 1,954 | 1,898 | 1,607 | 1,622 | 1,732 | 1,625 | 1,581 | 1,525 | 1,728 | 1,885 | 1,864 |
| Other non-financial assets | 382 | 517 | 373 | 381 | 440 | 377 | 363 | 333 | 378 | 426 | 406 |
| Financial assets | 571 | 610 | 381 | 216 | 574 | 467 | 266 | 220 | 212 | 197 | 229 |
| Cash and cash equivalents | 456 | 645 | 749 | 461 | 733 | 379 | 454 | 495 | 589 | 390 | 533 |
| **Current assets** | **6,110** | **6,588** | **5,668** | **5,508** | **6,368** | **5,600** | **5,305** | **4,967** | **5,431** | **5,658** | **5,890** |
| Assets held for sale | 0 | 76 | 236 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| **Current assets** | **6,110** | **6,664** | **5,904** | **5,508** | **6,368** | **5,600** | **5,305** | **4,967** | **5,431** | **5,658** | **5,890** |
| **Total assets** | **22,284** | **21,810** | **19,940** | **19,750** | **20,242** | **19,054** | **18,547** | **17,981** | **18,457** | **18,615** | **18,812** |

**Liabilities**

| in € million | 2021 FY | 2022 FY | 2023 FY | 2024 FY | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 FY | 2026 Q1 | 2026 Q2 | **2026 Q3** |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Issued capital | 466 | 466 | 466 | 466 | 466 | 466 | 466 | 466 | 466 | 466 | 466 |
| Reserves | 8,823 | 10,508 | 8,444 | 8,554 | 8,719 | 8,028 | 7,883 | 7,644 | 7,764 | 7,406 | 7,559 |
| **Equity attributable to shareholders of Evonik Industries AG** | **9,289** | **10,974** | **8,910** | **9,020** | **9,185** | **8,494** | **8,349** | **8,110** | **8,230** | **7,872** | **8,025** |
| Equity attributable to non-controlling interests | 83 | 82 | 76 | 80 | 82 | 65 | 64 | 64 | 68 | 61 | 65 |
| Total equity | 9,372 | 11,056 | 8,986 | 9,100 | 9,267 | 8,559 | 8,413 | 8,174 | 8,298 | 7,933 | 8,090 |
| Provisions for pensions and other post-employment benefits | 3,766 | 1,359 | 1,858 | 1,662 | 1,449 | 1,383 | 1,387 | 1,490 | 1,547 | 1,538 | 1,390 |
| Other provisions | 657 | 542 | 517 | 734 | 734 | 651 | 667 | 591 | 597 | 632 | 758 |
| Deferred tax liabilities | 628 | 661 | 608 | 638 | 633 | 625 | 629 | 576 | 592 | 616 | 616 |
| Other income tax liabilities | 195 | 246 | 268 | 254 | 258 | 268 | 246 | 228 | 231 | 275 | 258 |
| Financial liabilities | 3,531 | 4,117 | 3,502 | 3,162 | 3,629 | 3,586 | 3,663 | 3,476 | 3,471 | 3,717 | 2,936 |
| Other payables | 143 | 182 | 153 | 141 | 97 | 109 | 95 | 118 | 122 | 122 | 123 |
| **Non-current liabilities** | **8,920** | **7,107** | **6,906** | **6,591** | **6,800** | **6,622** | **6,687** | **6,479** | **6,560** | **6,900** | **6,081** |
| Other provisions | 892 | 732 | 606 | 923 | 955 | 695 | 724 | 787 | 818 | 734 | 1,017 |
| Other income tax liabilities | 211 | 189 | 124 | 87 | 86 | 63 | 59 | 58 | 79 | 73 | 76 |
| Financial liabilities | 477 | 429 | 1,153 | 1,034 | 941 | 1,215 | 830 | 689 | 684 | 748 | 1,408 |
| Trade accounts payable | 2,022 | 1,735 | 1,521 | 1,600 | 1,702 | 1,440 | 1,359 | 1,401 | 1,521 | 1,738 | 1,632 |
| Other payables | 390 | 501 | 457 | 415 | 491 | 460 | 475 | 393 | 497 | 489 | 508 |
| **Current liabilities** | **3,992** | **3,586** | **3,861** | **4,059** | **4,175** | **3,873** | **3,447** | **3,328** | **3,599** | **3,782** | **4,641** |
| Liabilities associated with assets held for sale | 0 | 61 | 187 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| **Current liabilities** | **3,992** | **3,647** | **4,048** | **4,059** | **4,175** | **3,873** | **3,447** | **3,328** | **3,599** | **3,782** | **4,641** |
| **Total equity and liabilities** | **22,284** | **21,810** | **19,940** | **19,750** | **20,242** | **19,054** | **18,547** | **17,981** | **18,457** | **18,615** | **18,812** |

## Group Net Financial Position

| in € million | 2021 FY | 2022 FY | 2023 FY | 2024 FY | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 FY | 2026 Q1 | 2026 Q2 | **2026 Q3** |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-current financial liabilities | -3,527 | -4,074 | -3,320 | -2,961 | -3,429 | -3,393 | -3,482 | -3,314 | -3,285 | -3,539 | -2,767 |
| Current financial liabilitites | -232 | -243 | -1,006 | -883 | -845 | -1,136 | -771 | -617 | -562 | -594 | -1,189 |
| **Financial debt** | **-3,759** | **-4,317** | **-4,326** | **-3,844** | **-4,274** | **-4,529** | **-4,253** | **-3,931** | **-3,847** | **-4,133** | **-3,956** |
| Cash and cash equivalents | 456 | 645 | 749 | 461 | 733 | 379 | 454 | 495 | 589 | 390 | 533 |
| Current securities | 446 | 413 | 261 | 128 | 482 | 285 | 121 | 124 | 117 | 121 | 122 |
| Other financial assets | 0 | 2 | 6 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 9 |
| **Financial assets** | **902** | **1,060** | **1,016** | **591** | **1,216** | **665** | **576** | **620** | **707** | **513** | **664** |
| **Net financial debt/cash as stated on the balance sheet** | **-2,857** | **-3,257** | **-3,310** | **-3,253** | **-3,058** | **-3,864** | **-3,677** | **-3,311** | **-3,140** | **-3,620** | **-3,292** |
| **Net financial debt/cash, discontinued operations** | **-** | **-** | **-** | **0** | **0** | **0** | **0** | **0** | **0** | **0** | **0** |
| **Net financial debt/cash including discontinued operations** | **-2,857** | **-3,257** | **-3,310** | **-3,253** | **-3,058** | **-3,864** | **-3,677** | **-3,311** | **-3,140** | **-3,620** | **-3,292** |

## Group Cash Flow Statement

| in € million | 2021 FY | 2022 FY | 2023 FY | 2024 FY | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 | 2025 FY | 2026 Q1 | 2026 Q2 | **2026 Q3** |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income before financial result and income taxes, continuing operations = EBIT | 1,173 | 942 | -243 | 577 | 299 | 236 | -25 | 68 | 578 | 229 | 163 | -6 |
| Depreciation, amortization, impairment losses/reversal of impairment losses on non-current assets | 1,073 | 1,568 | 1,841 | 1,117 | 240 | 260 | 428 | 275 | 1,203 | 239 | 376 | 317 |
| Result from investments recognized at equity | -8 | -12 | -10 | -21 | -2 | -3 | 0 | -9 | -14 | -1 | -2 | -2 |
| Gains/losses on disposal of non current assets | 43 | -50 | -1 | 22 | 15 | 4 | 5 | -13 | 11 | -2 | 7 | 5 |
| Change in inventories | -675 | -270 | 310 | -297 | -140 | 7 | 94 | 259 | 220 | -104 | -235 | -101 |
| Change in trade accounts receivable | -449 | 42 | 105 | 21 | -143 | -16 | 52 | 112 | 5 | -183 | -150 | 30 |
| Change in trade accounts payable and current advance payments received from customers | 680 | -257 | -157 | 74 | 185 | -228 | -67 | -32 | -142 | 187 | 205 | -98 |
| Change in provisions for pensions and other post-employment benefits | 83 | -19 | -55 | -48 | -4 | -13 | -28 | -4 | -49 | -8 | -17 | -6 |
| Change in other provisions | 207 | -149 | -141 | 535 | 37 | -341 | 40 | 10 | -254 | 27 | -63 | 394 |
| Change in miscellaneous assets/liabilities | -23 | 10 | 152 | -81 | -100 | 78 | 7 | -6 | -21 | 46 | -39 | 60 |
| Cash inflows from dividends | 19 | 19 | 25 | 27 | 0 | 19 | 0 | 7 | 26 | 0 | 18 | 0 |
| Tax payments relating to carve-out of the methacrylates business | - | - | - | - | - | - | - | - | - | - | - | |
| Cash inflows/outflows for income taxes | -308 | -174 | -232 | -213 | -2 | -38 | -25 | -55 | -120 | -23 | -34 | -31 |
| **Cash flow from operating activities** | **1,815** | **1,650** | **1,594** | **1,713** | **385** | **-35** | **481** | **612** | **1,443** | **407** | **229** | **562** |
| Cash outflows for investments in intangible assets, property, plant and equipment, investment property | -865 | -865 | -793 | -840 | -190 | -176 | -181 | -201 | -748 | -224 | -180 | -193 |
| Cash inflow/outflow for investments and divestments | -240 | 75 | -53 | 3 | 13 | 6 | 0 | 31 | 50 | 14 | 6 | 1 |
| Cash inflows/outflows relating to securities, deposits, loans and others | 23 | -3 | 161 | 137 | -352 | 199 | 164 | -3 | 8 | 3 | 9 | 1 |
| Cash inflows from interest | 12 | 16 | 32 | 37 | 18 | 5 | 3 | 10 | 38 | 4 | 4 | 4 |
| **Cash flow from investing activities** | **-1,070** | **-777** | **-653** | **-663** | **-511** | **36** | **-14** | **-165** | **-652** | **-203** | **-161** | **-187** |
| Cash outflows for dividends to shareholders of Evonik Industries AG | -536 | -545 | -545 | -545 | - | -545 | 0 | 0 | -545 | 0 | -466 | 0 |
| Cash inflow/outflow in connection with financial transactions | 67 | -126 | -2 | -30 | 2 | -15 | -4 | 8 | -9 | 18 | 3 | -4 |
| Cash inflow/outflow for financial liabilities | -293 | 72 | -177 | -646 | 414 | 229 | -331 | -388 | -76 | -101 | 222 | -186 |
| Cash outflows for interest | -94 | -73 | -99 | -109 | -14 | -10 | -53 | -24 | -101 | -29 | -29 | -47 |
| **Cash flow from financing activities** | **-856** | **-672** | **-823** | **-1,330** | **402** | **-341** | **-385** | **-407** | **-731** | **-112** | **-270** | **-237** |
| **Cash and cash equivalents as of beginning of period** | **563** | **456** | **645** | **749** | **461** | **735** | **379** | **-1,114** | **461** | **495** | **589** | **390** |
| **Change in cash, cash equivalents, exchange rates and others** | **-107** | **189** | **104** | **-288** | **273** | **-356** | **75** | **42** | **34** | **94** | **-199** | **138** |
| **Cash and cash equivalents as on the balance sheet as of end of period** | **456** | **645** | **749** | **461** | **734** | **379** | **454** | **-1,072** | **495** | **589** | **390** | **533** |

## Financial KPI Definitions

| | |
|---|---|
| **Adjusted EBIT** | Earnings before financial result and taxes, after adjustments. Earnings indicator showing Evonik's operating earnings performance irrespective of the structure of its assets. |
| **Adjusted EBITDA** | Earnings before financial result, taxes, depreciation and amortization, after adjustments. Earnings indicator showing Evonik's operating earnings performance irrespective of the structure of its assets and its investment profile. This is a cash flow-related indicator which is used in particular in the adjusted EBITDA margin to show the relationship to sales as a basis for comparison with competitors. |
| **Adjusted net income** | We use adjusted net income to assess the earnings power of the continuing operations, especially on a long-term view, and to forecast future development. The calculation starts from EBITDA after adjustment for special items. The financial result is then adjusted for income and expenses in connection with the acquisition/divestment of shareholdings and other income and expense items that, by nature or amount, do not form part of typical current financing activities. Further, we deduct amortization of intangible assets, as they mainly result from acquisitions, and adjust income tax for taxes on special items. |
| **Adjustments** | Evonik refers to the special items that are factored out when calculating the operational performance indicators adjusted EBITDA and adjusted EBIT as adjustments. They include restructuring, impairment losses/reversals of impairment losses, income and expenses in connection with the purchase/disposal of investments in companies, and other income and expense items that, due to their nature or amount, do not reflect the typical operating business. |
| **Free Cash Flow** | The free cash flow is a measure of the company's internal financing capacity. It shows the cash that is available to pay dividends, make acquisitions and repay borrowing. The free cash flow is calculated from the cash flow from operating activities, continuing operations, less outflows for capital expenditures on intangible assets, property, plant and equipment. |
| **ROCE** | The return on capital employed is a measure of the profitability of capital employed. It is calculated by dividing adjusted EBIT by the average capital employed in the reporting period. |

## ESG KPI Definitions

| | |
|---|---|
| **Value added in € million** | We use an impact valuation to regularly measure and analyze the direct and indirect impacts from an economic, ecological, and social perspective. This supplements our established analytical approaches. We anticipate that this will allow early identification of potential future opportunities and risks, make our business model more resilient, and improve understanding of the long-term value that our business activities create for society. We aim to assign a monetary value to individual indicators such as continuing development of employees, employment impacts, and global warming so they can be compared. Most of the factors used for this are publicly available. |
| **Sales share with "Next Generation Solutions"** | Sales share of products with superior sustainability benefits to customers ("Next Generation Solutions"); derived from sustainability analysis of our businesses based on the principles and content of the WBCSD Portfolio Sustainability Assessments (PSA)<br>For more information please see Evonik website:<br>Responsibility - Value Chain & Products - Sustainability Analysis |
| **Internal Investigations** | Internal investigations are initiated when there is a suspected violation of compliance rules (including the code of conduct, antitrust law and the rules on fighting and preventing corruption). Since 2018, the scope of reporting has covered all internal investigations in the Evonik Group. Before that, only the areas covered by the House of Compliance were included. |
| **Disciplinary Measures** | Disciplinary measures are taken as a result of an internal investigation. A disciplinary measure can result in an employee's dismissal, warning or reprimand, transfer to a different position or further awareness enhancement. In rare cases, legal proceedings (civil or criminal) had to be initiated. |
| **Raw Material Suppliers Covered by TfS Assessments** | This number indicates how many raw material suppliers have been covered by TfS assessments in that year. The chemical industry set up the Together for Sustainability (TfS) initiative in 2011 with the goal to harmonize global standards in the supply chain to create transparency and make it easier for both suppliers and customers to reliably assess and evaluate sustainability performance. This includes assessing the suppliers' quality, grade of environmental protection, safety, health, energy management, the assessment of potential risk factors. Evonik is one of the founding members of this initiative. |
| **Greenhouse Gas Emissions** | Scope 1: Evonik's direct energy and process-related emissions;<br>Scope 2: Purchased energy (net, total purchased power and steam - sale of power and steam to third parties; market-based approach);<br>Scope 3: Indirect emissions, including emissions from the production of purchased raw materials, packaging materials, capital goods, energy-related emissions outside scopes 1 and 2, emissions from inbound shipments of raw materials, from the disposal of production waste, business trips, commuting by employees, Evonik's fleet of vehicles, enregy requierements for offices and emissions from the disposal and recycling of products sold. |
| **Early Employee Turnover** | Turnover of newly hired employees within the first year of employment |
| **Management circles/ levels** | Management circle 1 = executive functions, i.e., top management functions in the Evonik Group<br>Management circle 2 = senior management functions, i.e., key functions in the divisions, regions, service units, and corporate functions<br>Management circle 3 = further management functions |
| **Occupational Health Performance Index** | This index shows the extent to which internal requirements have been implemented and goals achieved. It is calculated from two parameters from each of the following areas: occupational medicine, health promotion and emergency medical management. Both the quality and the scope of the measures are taken into account. The index is calculated annually. |
| **Specific water intake** in m3 freshwater per metric ton production | Freshwater usage in relation to production. |
| **Total water intake** | Evonik's consumption of freshwater is the total of drinking water, groundwater, surface water, and recycled water. Total water intake is the sum of total freshwater and salt water (sea water). |